RespireRx Pharmaceuticals Inc (fka RSPI)

[neuroinv]

Statistics have nothing to do with this at all. The experiments are the key element--which is why Cortex early on brought in people to go over the array of experiments they should do--and to make sure they didnt overlook anything, which could leave the FDA saying 'why don't you run this and come back to us..' (and that is still the 30% possibility, that the string gets run out still longer). The presentation is indeed the third component, which is why they are meeting with all of their consultants again in February to review all the data, and their strategy for presenting it.

NeuroInvestment